Trial
NCT02059850
NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Adult Synovial Sarcoma
Intervention
Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-02-03